16 September 2026 editorial review · Trial
ASK: free autoimmunity screening for US children and adults: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Checked official ASK program and locations pages. Current reach includes adults and home/Labcorp pathways, not just Colorado children; ages and unrelated teplizumab links corrected. Historical cohort outcomes remain distinct from current service access.
Sources for this record: ASK Research Program: eligibility and screening (community); ASK: screening locations and at-home options (community).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.